NEW YORK (360Dx) – Biovica, a Swedish biotechnology company, aims to launch an assay for predicting and monitoring treatment response in cancer patients by 2020.

CEO Anders Rylander said the company will initially market its DiviTum assay for use in breast cancer, though it could be used to monitor cell proliferation in all cancer types. Biovica will seek regulatory clearance for its test in the US as well as in Europe, and is currently engaged in nearly a dozen studies aimed at assessing the test's performance in both regions, he said.

Get the full story with
GenomeWeb Premium

Only $95 for the
first 90 days*

GenomeWeb Premium gives you:
✔ Full site access
✔ Interest-based email alerts
✔ Access to archives

Never miss another important industry story.

Try GenomeWeb Premium now.

You may already have institutional access!

Check if I qualify.

Already a GenomeWeb or 360Dx Premium member?
Login Now.

*Before your trial expires, we’ll put together a custom quote with your long-term premium options.

Not ready for premium?

Register for Free Content
You can still register for access to our free content.

Publication of He Jiankui's work on gene-edited infants would raise ethical concerns for journals, Wired and others report.

The New York Times reports that evidence linking trauma in one generation to epigenetic effects that influence subsequent generations may be overstated.

ScienceInsider reports that US National Institutes of Health researchers were told in the fall they could not obtain new human fetal tissue.

In PNAS this week: skin pigmentation evolution among KhoeSan, biomarkers for dengue virus progression, and more.